RGD

Item no.	HY-P0278-1mg
Manufacturer	MedChem Express
CASRN	99896-85-2
Amount	1 mg
Quantity options	100 mg 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer
Type	Inhibitors
Specific against	other
Purity	99.12
Citations	[1]Hersel U, et al. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials. 2003 Nov;24(24):4385-415. Cancer Sci. 2020 May 24;111(8):2803-2813. \|Int J Biol Macromol. 2023 Aug 31;126499.\|Mater Sci Forum. 2019, 955: 68-73.\|Nat Commun. 2024 Apr 18;15(1):3343.\|Chem Eng J. 5 February 2022, 135088.\|Colloid Polym Sci. 2023 Feb 27.
Smiles	O=C(O)C[C@@H](C(O)=O)NC(CNC([C@H](CCCNC(N)=N)N)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Gly-Cys-Gly-Tyr-Gly-Arg-Gly-Asp-Ser-Pro-Gly, GCGYGRGDSPG
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Integrin
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Molecular Weight	346.34
Product Description	RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 1.94 mg/mL (ultrasonic; adjust pH to 3 with HCl)\|H2O: 10 mg/mL (ultrasonic)
Manufacturer - Pathway	Cytoskeleton
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P0278-1mg-safety-datasheet.pdf